Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

President Donald Trump's executive order mandates drugmakers to lower prices to match those in affluent nations, threatening ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Current health news covers major investments by Merck Animal Health and Gilead Sciences in the U.S., regulatory decisions ...

Shares of Alphamab Oncology plunged 14.4% to HK$6.28, leading declines in Hong Kong-listed pharmaceutical stocks.Meanwhile, ...

Eli Lilly's stock price rise of 9% YTD might ... The most concerning of the potential drags on LLY were its recent legal issues. The company had just sued the government's Health Resources and ...

April 23 (UPI) --Eli Lilly Wednesday filed lawsuits against ... "Their use remains appropriate and legal when tailored to individual patient needs and prescribed by a licensed medical provider ...

President Donald Trump’s latest bid to slash prescription drug prices has once again stirred heated debate about the high ...

Eli Lilly (NYSE:LLY ... is also over. Earlier in April, Lilly took legal action against two compounding pharmacies seeking to stop them from manufacturing and marketing compounded tirzepatide.